CAR-T cell therapy targeting the HER2 antigen on gastric cancer cells has shown cytotoxic activity against patient-derived HER2-positive gastric cancer cells and also demonstrated tumour inhibition and prolonged survival in xenograft models [84]. The gene discussed is ERBB2; the disease is gastric cancer.